畅通政策传导渠道 每年岁末年初，政府搭台，推动国谈药品与定点医药机构对接，这在上海已成为常态。 作为今年上海推动国谈创新药落地的首场重要活动，本次推介会聚焦新进医保目录的"新优药械"， 围绕入院应用关键环节，搭建起"政府—医院—企业"三方联动沟通平台，破解创新药入院流程烦琐、信 息不对称等痛点难点问题。 为加快创新产品应用推广，2022年，由市生物医药产业主管部门牵头，联合市卫健委、市医保局、 申康中心等部门，建立了支持地产新药入院应用绿色通道的工作机制《上海市生物医药"新优药械"产品 目录》（以下简称《目录》）。截至2025年底，《目录》已发布7批次，纳入220件产品，产品总销售额 逐年提高，促进入院作用明显。 记者 周程祎 林子璐 2025版国家医保药品目录已于今年1月1日正式执行，这是国家医保局成立以来的第八次目录调整。 本次调整新增药品114种，其中一类创新药达50种，涵盖肿瘤、罕见病、慢性病等多个治疗领域，为临 床用药提供了更多选择。 如何加速创新药临床应用落地，惠及更多患者？在15日举行的上海市2026年首场新增国谈创新药推 介会上，政府、医院、药企三方代表再次坐到了一起，探讨新产品，共话新机遇。 ...

Group 1 - The core viewpoint of the news is that 罗欣药业 reported a revenue growth of 11.99% to 2.647 billion yuan for the year 2024, but also faced a net loss of 962 million yuan [1] - The company made significant progress in the hospital access work for its innovative drug, 替戈拉生片, and successfully obtained new indications, indicating a long-term and complex process for drug promotion that requires continuous investment and effort [1] - To enhance brand and product recognition, the company increased its marketing investment, laying the foundation for gradually expanding market share in the future [1] Group 2 - 上药罗欣 achieved a performance completion rate of 95.76% in 2023, but faced pressure in 2024 due to market environment changes and industry policy adjustments, leading to a significant gap between its operational situation and performance commitment targets [2] - The company recognized a non-recurring loss due to adjustments in the fair value of financial liabilities based on 上药罗欣's performance and future expectations [2] - The company reported signs of asset impairment and, following the principle of prudence, made provisions for impairment based on evaluation results and market conditions [2] Group 3 - In the Q1 2025 financial report, 罗欣药业 achieved a net profit of 5 million to 7 million yuan, marking a turnaround from losses year-on-year [2] - The market share of 替戈拉生片 significantly increased, and channel coverage continued to expand due to the steady progress of the commercial team's efforts in drug promotion and hospital access [2] - The company effectively improved its operating cash flow and reduced bad debt losses through a special collection of receivables [2]